68Ga-DOTATATE PET/CT在非神经内分泌肿瘤中的应用:图谱评述
本文以图谱评述形式展示非神经内分泌肿瘤(如非霍奇金淋巴瘤、转移性脑膜瘤、乳腺癌、甲状腺腺瘤及乳头状癌)因生长抑素受体高表达而在68Ga-DOTATATE PET/CT上出现假阳性摄取的表现,提醒识别此类过表达以避免误判。
要点
- 生长抑素受体并非神经内分泌肿瘤特有,多种非神经内分泌肿瘤也可高表达。
- 非霍奇金淋巴瘤、转移性脑膜瘤、乳腺癌、甲状腺腺瘤及乳头状癌可致68Ga-DOTATATE PET/CT假阳性。
- 识别生长抑素受体过表达的非神经内分泌病变有助于避免PET/CT图像误判。
核心结论
- 68Ga-DOTATATE是肿瘤学应用中有价值的示踪剂,但应识别生长抑素受体过表达的病理情况以防止PET/CT图像误判。
研究设计与样本
- 本文为图谱评述,展示非霍奇金淋巴瘤、转移性脑膜瘤、乳腺癌、甲状腺腺瘤及乳头状癌因高摄取导致的68Ga-DOTATATE PET/CT假阳性表现。
主要发现
- 非霍奇金淋巴瘤、转移性脑膜瘤、乳腺癌、甲状腺腺瘤及乳头状癌可出现68Ga-DOTATATE高摄取,导致假阳性PET/CT结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET-CT with somatostatin analogs labeled with Ga is increasingly recognized as the best imaging modality for the evaluation of well-differentiated neuroendocrine tumors (NETs). However, somatostatin receptor (SSR) is not an exclusive marker for NET. A variety of tumors other than NETs express SSR, leading to a significant risk of false-positive PET/CT results. We illustrate false-positive Ga-DOTATATE PET/CT findings due to high uptake by non-Hodgkin lymphoma, metastatic meningioma, breast cancer, thyroid adenoma, and papillary carcinoma. Although Ga-DOTATATE is a noteworthy tracer for oncological application, pathological conditions with overexpression of SSR should be recognized to prevent misinterpretation of PET/CT images.
引用
- Yamaga LYI, Wagner J, Funari MBG, et al. 68Ga-DOTATATE PET/CT in Nonneuroendocrine Tumors: A Pictorial Essay. Clin Nucl Med. 2017. PMID: 28240663. doi:10.1097/RLU.0000000000001620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。